drugset
drugset / Trial / NCT03393507

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

NCT03393507 ↗

Phase 2 Unknown 34 enrolled The People's Hospital of Leshan Jiangsu HengRui Medicine Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer

Timeline

Start
2017-08-01
Primary completion
2018-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg Oral
Background Carboplatin Small molecule 4 unknown Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Other
Background Cisplatin Other / unclassified 100 mg/m2 Other
Background Docetaxel Small molecule 60 mg/m2 Other
Background Docetaxel Small molecule 75 mg/m2 Other
Background Paclitaxel Small molecule 135 mg/m2 Other
Background Paclitaxel Small molecule 175 mg/m2 Other

Indications

chemotherapy-induced toxicity ovarian cancer